AMULET vs. WATCHMAN: Appendage Closure Devices, Head to Head

This research was designed to compare the double closure system of the AMULET device with the WATCHMAN (an evidence-backed proven device).

AMULET vs WATCHMAN. Los dispositivos de cierre de orejuela cabeza a cabeza

In that context, to prevent stroke in patients with non-valvular atrial fibrillation, the Amplatzer AMULET device was non-inferior in both safety and efficacy compared with the WATCHMAN. Atrial appendage occlusion in itself improved with AMULET, but with a higher rate of procedure-related complications that decreased with operator experience.

This study randomized 1878 patients with non-valvular atrial fibrillation and increased risk of stroke 1:1 to atrial appendage occlusion with either the AMULET or the WATCHMAN device.

There were two primary endpoints: one for safety (a composite of procedure-related complications, all-cause mortality, or major bleeding at 1 year) and one for efficacy (a composite of ischemic stroke or systemic embolism at 18 months), plus total appendage occlusion at 45 days.

The secondary endpoints were combinations of the aforementioned events.

The AMULET device was non-inferior to the WATCHMAN in the primary efficacy endpoint (14.5% vs. 14.7%; 95% confidence interval: 3.42 to 3.13; p < 0.001 for non-inferiority).

Major bleeding and all-cause mortality were also similar between devices (10.6% vs. 10.0% and 3.9% vs. 5.1%, respectively).


Read also: Asymptomatic Carotid Lesions and Cognitive Impairment: Does Intervention Play a Role?


The AMULET device almost doubled peri-procedural complications (4.5% vs. 2.5%)—primarily due to pericardial effusion and device embolization.

Major bleeding rates were similar in both groups (11.6% vs. 12.3%), while effective atrial appendage occlusion was higher with the AMULET device.

Conclusion

The AMULET atrial appendage occluder device was non-inferior in terms of safety and efficacy to the WATCHMAN device for stroke prevention in patients with non-valvular atrial fibrillation. Periprocedural complications observed with the AMULET decreased with operator experience.

amulet-versus-watchman

Original Title: AMPLATZERTM AMULETTM LEFT ATRIAL APPENDAGE OCCLUDER VERSUS WATCHMANTM DEVICE FOR STROKE PROPHYLAXIS (AMULET IDE): A RANDOMIZED CONTROLLED TRIAL.

Reference: Dhanunjaya Lakkireddy et al. 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...